Intellia Therapeutics Inc.

In News

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics - Jun 13, 2026

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? - Yahoo Finance

Yahoo Finance - Jun 20, 2026

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late - Stocktwits

Stocktwits - Jun 19, 2026

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 - Intellia Therapeutics

Intellia Therapeutics - Jun 01, 2026

Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution - Yahoo Finance

Yahoo Finance - Jun 05, 2026

NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits

Stocktwits - Jun 21, 2026

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics

Intellia Therapeutics - Apr 27, 2026

Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength? - Yahoo Finance

Yahoo Finance - Jun 16, 2026

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema - Intellia Therapeutics

Intellia Therapeutics - Apr 27, 2026

Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update - Yahoo Finance

Yahoo Finance - Jun 04, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics

Intellia Therapeutics - Jun 05, 2026

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance

Yahoo Finance - May 07, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment